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Expression profile of leukocyte genes activated by anti-neutro- Anti-neutrophil cytoplasmic autoantibodies (ANCA)
phil cytoplasmic autoantibodies (ANCA). directed against proteinase 3 (PR3-ANCA) or myeloper-
Background. Anti-neutrophil cytoplasmic autoantibodies oxidase (MPO-ANCA) are detected in patients with Weg-(ANCA) induce neutrophil activation in vitro with release of
ener’s granulomatosis, microscopic polyangiitis, pauci-injurious products that can mediate necrotizing vasculitis in vivo.
immune necrotizing glomerulonephritis, and Churg-StrausThe importance of ANCA IgG F(ab)2-antigen binding versus
Fc receptor engagement in this process is controversial. We syndrome (ANCA disease) [1, 2]. Determining the mech-
propose that ANCA-antigen binding affects cell signaling path- anism/s of ANCA pathogenesis is important for delineat-
ways that can result in changes of gene expression. ing the basis of the disease, predicting risk and definingMethods. Microarray GeneChip analysis and real-time, quanti-
new avenues of treatment for these individuals. Existingtative PCR (TaqMan) was used to probe for transcripts in
leukocytes from patients (in vivo gene expression study) and data, generated in vitro by treating neutrophils from
in leukocytes treated with ANCA IgG or ANCA-F(ab)2 (in healthy volunteers with ANCA from patients, are envis-
vitro gene expression study). aged as mimicking in vivo interactions. Results showedResults. Microarray gene chip analysis showed that ANCA
that ANCA induce primed neutrophils and monocytesIgG and ANCA-F(ab)2 stimulate transcription of a distinct
to undergo respiratory burst, releasing toxic granule con-subset of genes, some unique to whole IgG, some unique to
F(ab)2 fragments, and some common to both. DIF-2, COX-2, stituents into the microenvironment [3–6]. Neutrophils
and IL-8 were identified as genes responsive to ANCA signal- also respond to ANCA by up-regulating the transcrip-
ing and were selected for in depth evaluation. In vitro DIF-2
tion of genes, resulting in protein increases of cytokinesand IL-8 were increased by both ANCA IgG and F(ab)2, but
such as interleukin (IL)-1 and IL-8 [7, 8]. We hypothe-COX-2 only by MPO-ANCA F(ab)2. In vivo DIF-2 levels were
increased in leukocytes of ANCA patients, which correlated sized that leukocytes exposed to ANCA, both in vivo
strongly with disease activity and ANCA titer. DIF-2 was not and in vitro, would produce specific patterns of gene ex-
increased in patients in remission or in disease control patients
pression. Moreover, we proposed that specific antibody-(systemic lupus erythematosus and IgA nephropathy). COX-2
antigen interactions, through the F(ab)2 portion of thegene expression was significantly increased in patients with
active disease, while IL-8 was increased in remission. ANCA molecule, could mediate the changes, at least in
Conclusions. The data indicate that leukocyte genes are acti- part, in gene expression. To test these hypotheses, differ-
vated in vitro by both ANCA Fc and ANCA F(ab)2 pathways entially expressed genes were determined by use of oli-and that in vitro activation mimics changes in circulating leuko-
gonucleotide-based microarrays. A number of differen-cytes of patients with ANCA disease. Increased levels of DIF-2
in patient leukocytes strongly correlate with severity of disease tially expressed genes were identified that appear to be
in kidney tissue. The observations indicate a previously unrec- associated with ANCA disease. Our study examined the
ognized role for DIF-2 in ANCA-mediated inflammation, which expression of three of these genes, differentiation-depen-raises the possibility that DIF-2 has an important role in other
dent gene 2 (DIF-2), interleukin-8 (IL-8) and cyclooxy-types of inflammation.
genase-2 (COX-2), using quantitative, real-time polymer-
ase chain reaction (TaqMan-PCR). DIF-2, also knownKey words: DIF-2 in ANCA, inflammation, Churg-Straus syndrome,
as radiation-inducible immediate-early gene (IEX-1),Wegener’s granulomatosis, microscopic polyangiitis, pauci-immune
glomerulonephritis, gene transcription, cell signaling. gly96 in mouse, and pituitary adenylate cyclase-activat-
ing polypeptide responsive gene (PRG1) in rat, is of par-Received for publication December 3, 2001
ticular interest because of its potential role in monocyteand in revised form April 19, 2002
Accepted for publication June 13, 2002 differentiation [9–11]. The results presented here dem-
onstrate that leukocytes from patients with ANCA dis- 2002 by the International Society of Nephrology
1638
Yang et al: Expression profile of leukocytes activated by ANCA 1639
ease express a unique set of genes and that gene expres- MPO-ANCA patients was 2.3  1.4 mg/dL. When avail-
able, additional samples were collected from patientssion changes correlate with severity of disease. This gene
expression profile is comparable to that seen in neutro- over the course of their disease. Therefore, the total
number of samples analyzed in the ANCA disease groupphils treated in vitro with ANCA-IgG. In addition, and
central to understanding mechanism(s), we found that increased to 51. Disease control groups consisted of pa-
tients with systemic lupus erythematosus (SLE; N  31;ANCA-F(ab)2 fragments produce similar results to that
of the whole IgG molecule, indicating that antigen-anti- mean serum creatinine 1.4  1.3 mg/dL) and IgA ne-
phropathy (N  18; mean creatinine 1.4  0.8 mg/dL).body interactions are involved in the activation of gene
transcription. Moreover, these studies lend themselves The normal control group consisted of leukocytes do-
nated by healthy volunteers (N  32).to insights into the biologic diversity of ANCA disease
and into the inherent variability in leukocytes from
Purification of leukocyte total RNAhealthy donors with respect to their response to ANCA.
Blood was collected into ethylenediaminetetraacetic
acid (EDTA)-containing tubes. Erythrocytes were lysed
METHODS
(0.83% NH4Cl, 10 mmol/L KHCO3, and 0.1 mmol/L
Preparation of IgG and F(ab)2 fragments EDTA) [16]. Remaining leukocytes were washed with
Hank’s balanced salt solution (HBSS). For in vivo stud-Plasma was obtained by aphaeresis from 12 patients
with Wegener’s granulomatosis or microscopic polyangi- ies, leukocytes from patients were lysed immediately in
RNA STAT-60 (Tel-Test “B,” Friendswood, TX, USA)itis according to the Chapel Hill nomenclature systemic
definitions [12]. These patients were positive for either and RNA was extracted as previously described [17].
Contaminating DNA was removed using RNeasy MiniPR3-ANCA (N 6) or MPO-ANCA (N 6) as defined
by anti-PR3 and anti-MPO enzyme-linked immunosor- Kit (Qiagen, Valencia, CA, USA). RNA quality was spec-
trophotometrically determined by OD 260/280 nm ratiosbent assay (ELISA) and standard indirect immunofluo-
rescence microscopy assay (IFA) [13, 14]. Plasma pro- and by agarose gel visualization of 28S and 18S ribosomal
RNA ratios. For in vitro studies, leukocytes from healthycured from four healthy individuals was used as the
control. IgG was purified by ammonium sulfate precipi- volunteers were primed with 2 ng/mL recombinant tu-
mor necrosis factor- (TNF-; R&D Systems, Minneap-tation and HiTrap Protein G column chromatography
using fast protein liquid chromatography (FPLC; Phar- olis, MN, USA) for 15 minutes. Primed leukocytes were
treated with multiple PR3-ANCA IgG, MPO-ANCAmacia Biotech, Uppsala, Sweden) as previously de-
scribed [3, 15]. Portions of the PR3-ANCA (N  3), IgG or normal IgG (200 g/mL) or equivalent moles of
corresponding F(ab)2 [147 g/mL for MPO-ANCA andMPO-ANCA (N  4), and normal (N  4) IgG were
digested with pepsin (Pierce, Rockford, IL, USA) to normal F(ab)2; 220 g/mL for PR3-ANCA F(ab)2-
adjusted for activity] in HBSS with calcium and magne-generate F(ab)2 fragments. Digestion products were
subjected to a Protein G column and subsequent dialysis sium (HBSS) for 0.5, 1, 2, or 4 hours at 37	C. RNA
was isolated as described above. Leukocytes from eightto remove uncleaved molecules and the resulting Fc por-
tions. Purity of intact IgG and their F(ab)2 fragments donors were analyzed in duplicate in eight independent
experiments.was determined by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) electrophoresis,
Microarray data processingIFA, and anti-PR3 and MPO ELISA. Epitope binding
activity of MPO-ANCA-F(ab)2 fragments was equiva- The methodologies of Affymetrix microarray comple-
mentary DNA labeling, hybridization, and scanning usedlent to that of parent intact MPO-ANCA IgG, while the
activity of PR3-ANCA-F(ab)2 fragments was 67% of were according to those described in detail by Affymetrix
(Palo Alto, CA, USA). DNA microarray chip analysesPR3-ANCA IgG by ELISA. All preparations were
passed through an AffinityPak Endotoxin Removal Col- were performed to develop an ANCA-related leukocyte
expression profile. Profiles from in vitro exposed leuko-umn (Pierce) and determined to be endotoxin-free.
cytes from an individual with either normal-IgG or
Patients ANCA-IgG and the corresponding F(ab)2 components.
Approximately 131 genes were detected as differentiallyPatients were identified though the Glomerular Dis-
ease Collaborative Network enrolled between October regulated (65 up and 66 down) after analysis of five
separate experimental samples. This set of genes was1999 and May 2001. Patients with ANCA-associated sys-
temic small vasculitis disease (N  34, composed of 19 identified using an Affymetrix Human E-chip microarray
of 7129 genes consistently expressed across a range ofPR3-ANCA and 15 MPO-ANCA patients) were ranked
for disease severity on the basis of clinical information tissues at a variety of expression levels. These genes
were then used to normalize the data from differentas reviewed by a physician. The mean serum creatinine
of PR3-ANCA patients was 2.2  2.0 mg/dL and for microarray experiments. Briefly, the expression levels of
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the preselected genes were scaled to a “standard experi- with TNF-. Primed leukocytes were treated with multiple
ANCA or normal IgG or their corresponding F(ab)2 frag-ment” and the geometric mean of the scaling factors was
ments plus 50 mol/L ferricytochrome C in HBSS pluscalculated. This value served as the normalization factor
calcium and magnesium for 45 minutes at 37	C. The ab-for all genes represented on the microarray. The fold
sorption of the supernatant with and without SOD (125change between the level of expression of any two genes
g/mL) was determined, as previously reported [3, 15],on two different microarrays was calculated according
at 550 nm and results were expressed as nmol/L O
2 re-to the protocol supplied by Affymetrix. Expression data
lease/2.5106 leukocytes/45 minutes. TNF-- primed cellswere initially analyzed with the GeneChip software (Affy-
treated with 10
7 mol/L N-formyl-met-leu-phe (fMLP)metrix). Arrays were globally scaled to an average inten-
served as a positive control. Leukocytes from six donorssity of 2500. A value of 200 was assigned to all intensity
were analyzed in duplicate in six independent experiments.measurements below 200 before differences in intensities
were calculated. Three parameters were used for analy-
Analysis of DIF-2 protein levelssis, average difference intensity change, difference call,
For in vitro studies, TNF--primed leukocytes wereand fold change. Gene expression levels that varied less
treated with normal or ANCA IgG for six6 hours. For inthan 2.5-fold relative to the biological base line or had
vivo studies, leukocytes from patients were pelleted anda difference call of “no change,” as determined by the
flash frozen. Leukocytes were lysed with Laemmli sampleGeneChip algorithms, were considered unchanged.
buffer and boiled for five minutes. Aliquots (50 g
total protein) were subjected to sodium dodecyl sulfate–Quantitative PCR assay
polyacrylamide gel electrophoresis SDS-PAGE (15%Reagents for quantitative polymerase chain reaction
acrylamide) and transferred to nitrocellulose (Schleicher(PCR) were from the TaqMan EZ-RT PCR kit (Ap-
and Schuell, Keene, NH, USA) at 100V for one hourplied Biosystems, Foster City, CA, USA). Reverse tran-
and probed using goat anti-human IEX-1 (Santa Cruz Bio-scription (RT) and PCR assays were performed in dupli-
technology, Santa Cruz, CA, USA) and anti-goat, horse-cate using a Perkin-Elmer 7700 TaqMan PCR machine.
radish peroxidase-conjugated secondary antibody (Chem-Standard RT extension, PCR annealing and amplifica-
icon, Temecula, CA). Immunodetection was accomplishedtion temperatures were used as detailed by the Perkin-
by chemiluminescence (Pierce). Proteinase 3 (PR3) West-Elmer TaqMan manual. Primers and probe for DIF-2
ern blots were used as protein loading comparisons.were designed using the Perkin-Elmer software, Primer
Express (Applied Biosystems). Primers and probe for Statistics
IL-8 and COX-2 were a generous gift from Dr. Rob Comparisons between two groups were made using
Silbajoris (EPA, Chapel Hill, NC, USA). Primers and Wilcoxon rank-sum tests. Overall differences between
probe for cyclophilin A were purchased from Applied multiple groups were tested using the non-parametric
Biosystems. Oligonucleotide sequences are as follows: Kruskal-Wallis test and analysis of variance (ANOVA)
DIF-2 (forward primer GGT ACA TCC TCG ACG on ranked values of DIF-2, COX-2 and IL-8. If differ-
GCA TCT, reverse primer GTG CCT CTT TGC TGC ences were found overall, then Bonferroni t tests were
TTT CAC, probe CTC CAG CAT TCT CAA CTC CGT performed on the ranked values, with comparisons at
CTG TCT ACT G); IL-8 (forward primer TTG GCA the 0.05 level of significance set for detecting differences
GCC TTC CTG ATT TC, reverse primer TAT GCA between groups.
CTG ACA TCT AAG TTC TTT AGC A, probe CCT
TGG CAA AAC TGC ACC TTC ACA CA); and
RESULTSCOX-2 (forward primer GAA TCA TTC ACC AGG
Microarray GeneChip analysis to screen forCAA ATT G, reverse primer TCT GTA CTG CGG
biologically relevant genesGTG GAA CA, probe TCC TAC CAC CAG CAA
CCC TGC CA). Relative quantitative level of samples To test the hypothesis that gene expression profiles of
was determined by standard 2(
Ct) calculations and ex- leukocytes exposed to ANCA IgG and/or ANCA-F(ab)2
pressed as fold-change of a single reference control sam- fragments is unique compared to that induced by other
ple. Cyclophilin A levels were used to standardize RNA IgG molecules, leukocytes from a healthy donor were
concentrations from sample to sample. treated in vitro and RNA transcript levels were deter-
mined. Using Affymetrix GeneChip array analyzes, a
Detection of superoxide release subset of genes was identified that differed in their ex-
Superoxide release was measured as superoxide dis- pression levels by 2.5-fold or greater during exposure to
mutase (SOD)-inhibitable reduction of ferricytochrome either intact PR3-ANCA or MPO-ANCA IgG, compared
C, using discontinuous assay [18]. Leukocytes were pre- to one-hour time-matched controls. A subset of genes
treated with 5 g/mL cytochalasin B (Sigma Chemical were affected by both ANCA-IgG and ANCA-F(ab)2
fragments (Table 1). However, specific genes were re-Co., St. Louis, MO, USA) for five minutes and primed
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sponsive to ANCA-F(ab)2 only. These data are consid- Comparison of functions in vitro: ANCA-induced
superoxide release versus transcription inductionered to represent a screen for physiologically relevant
genes. To corroborate the biological significance of mi- Anti-neutrophil cytoplasmic autoantibodies IgG have
croarray data, confirming studies must be conducted. the capacity to induce neutrophil activation and superox-
ide release [3]. Variability in the magnitude of this effect
Transcriptional activation by ANCA IgG and ANCA has been attributed to variations in ANCA IgG prepara-
F(ab)2: An in vitro study tions from individual patients and to variations in re-
TaqMan PCR was used to validate and quantitatively sponse of leukocytes from healthy volunteers. Similar
assess genes of potential significance. From the genes variations were observed in the ability of some ANCA
identified by microarray analysis, DIF-2 mRNA levels IgG to induce DIF-2 transcription. It was of interest to
were increased 6.1-fold by PR3-ANCA-F(ab)2, and C determine if ANCA IgG from a particular patient that
OX-2 was increased 2.6-fold. DIF-2 was selected for com- is deficient in activating superoxide release in vitro would
parative expression studies because of its association likewise be deficient in activating transcription of DIF-2.
with stress responses and with differentiation processes Leukocytes from six donors were treated with normal
[10]. COX-2 and IL-8 were included because of their IgG, MPO-ANCA IgG, PR3-ANCA IgG or the corre-
biological significance in inflammatory diseases. sponding F(ab)2 fragments and superoxide release was
To examine changes in gene expression resulting from measured. Both intact ANCA IgG and F(ab)2 fragments
ANCA-induced signaling, leukocytes from healthy vol- increased superoxide release more proficiently than the
unteers were treated with two normal IgG, two PR3- normal counterparts (Table 3). However, comparison of
ANCA IgG, and two MPO-ANCA IgG in vitro. The individual ANCA IgG preparations showed that there
relative change in mRNA levels of three genes, pre- was no direct correlation between the ability of the
viously identified by microarray chip analysis DIF-2, ANCA IgG to induced superoxide release and their ca-
COX-2 and IL-8, were determined by TaqMan PCR, pacity to induce transcription (Fig. 2). For example, PR3-
and compared to that of mock-treated controls. DIF-2, ANCA from patient #3 induced relatively high levels of
COX-2 and IL-8 were increased by ANCA IgG above superoxide release, while it ranked low in DIF-2 activa-
that of normal IgG in a time-dependent manner (Fig. 1 tion. Conversely, PR3-ANCA from patient #1 ranked
A-C). To examine further the specificity of autoantibody high in both measures.
leukocyte interactions, leukocytes were treated with cor-
Gene expression of leukocytes from ANCA patients:responding F(ab)2 fragments. ANCA F(ab)2 increased
An in vivo studyDIF-2, COX-2 and IL-8 (Fig 1 D-F), above that of nor-
mal F(ab)2. Interestingly, the capacity of ANCA F(ab)2 The in vitro results strongly support the hypothesis
fragments to induced transcription was similar to that of that part of the pathogenic activity of ANCA involves
the intact ANCA IgG molecules. In fact, microarray ANCA-induced signaling events that result in changes
gene chip analysis showed that ANCA IgG and ANCA in gene expression. We hypothesized that leukocyte gene
F(ab)2 stimulate transcription of a distinct subset of expression profiles of patients with circulating ANCA
genes, some unique to whole IgG, some unique to F(ab)2 would mimic those seen in the in vitro studies. Leuko-
fragments, and some common to both (Table 1). cytes from patients with active ANCA disease at various
To establish that the phenomenon of stimulated gene stages of severity (N  39) and from ANCA patients in
expression due to ANCA stimulation is true for multiple remission (N  12) were analyzed by Q-PCR for the
leukocyte donors, the studies were expanded to include relative expression levels of DIF-2, COX-2 and IL-8,
the analysis of eight donors, each treated with normal and values were compared to those obtained from pa-
IgG (N  4), MPO-ANCA IgG (N  6), PR3-ANCA tients with SLE (N  31) or IgA nephropathy (N  18),
IgG (N  6), normal F(ab)2 (N  4), MPO-ANCA and with healthy volunteers (N  32; Fig. 3 and Table
F(ab)2 (N  4), and PR3-ANCA F(ab)2 (N  3) for 4). DIF-2 levels from leukocytes of healthy individuals
one hour. These data are summarized in Table 2. ANCA were 3.1  1.8-fold above the reference control, while
IgG and F(ab)2 were more proficient at activating tran- ANCA patients with active disease showed increased
scription of DIF-2 and IL-8 than normal-IgG or F(ab)2. levels of 6.3  3.9-fold (P  0.05). This increase was not
COX-2 levels were increased above controls with ANCA observed in ANCA patients in remission (3.8  3.3-
IgG and ANCA F(ab)2 exposures, however, with statis- fold), in SLE patients (2.7  2.3-fold) or in IgA patients
tical significance in the MPO-ANCA F(ab)2-treated (2.2  1.0-fold). Individual patient’s values are shown
group only. The data indicate that both intact ANCA in Figure 3A. When COX-2 levels were compared among
IgG and their respective F(ab)2 fragments induce DIF-2, the groups (Fig. 3B), a significant increase was observed
IL-8, and in some cases COX-2, expression above that in the active ANCA patients (5.0  5.5-fold, P  0.05)
and SLE patients (6.6  7.7-fold, P  0.05), but not inof normal IgG or F(ab)2.
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Fig. 1. In vitro analysis of the time course of changes in the relative mRNA level of (A and B) DIF-2, (C and D) COX-2 and (E and F ) IL-8
by TaqMan-PCR. TNF--primed leukocytes from a healthy volunteer were stimulated by normal or ANCA IgG (A-C) or their respective F(ab)2
fragments (D-F). The values represent the fold-change compared to non-incubated, untreated controls. Each point represents the average value
of two treatments with different IgG or F(ab)2 preparations and all experiments were performed in duplicate. Symbols are: () untreated; ()
normal IgG; () MPO-ANCA F(ab)2; () PR3-ANCA F(ab)2.
ANCA patients in remission (4.8  5.9), in IgA patients to active ANCA disease (5.9 8.5-fold), IgA (4.3  3.0-
fold), SLE (4.9 3.9-fold) and healthy individuals (3.6(2.9  2.0-fold), or in healthy donors (1.7  1.1-fold).
IL-8 levels were significantly increased in ANCA pa- 3.4-fold; Fig. 3C). Further analysis indicated that patients
categorized as ANCA had an increase in IL-8 levels thattients in remission (9.5  9.0-fold P  0.05), compared
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approached significance (N  8, 10.0  8.7-fold), com-
pared to ANCA (N  19, 6.6  10.3) and ANCA
(N  12, 2.2  1.4). Of note, the statistical comparisons
were made using non-parametric methods to determine
shifts in distribution, as opposed to differences in means,
to avoid outliers having an influential effect.
We determined if the observed increase in DIF-2 lev-
els in leukocytes from active ANCA patients could be
correlated with the severity of disease (Fig. 3D). Disease
activity was judged by one of us (RJF) based on pre-
dictors that consider physical findings, patient history,
pathological and clinical laboratory reports, and the
overall longitudinal clinical course as described in Nach-
man et al’s study [19]. DIF-2 levels in ANCA patients
in remission with mild disease activity (active) were
similar to that of healthy volunteers at 3.7  3.0-fold
above the baseline reference sample. However, in ANCA
patients with moderate disease activity (active) DIF-2
levels increased to 7.2 4.6-fold and with severe disease
activity (active) 6.4  2.5-fold, both statistically
higher than the healthy donors (P  0.05). Moreover,
there was a direct correlation between ANCA titer and
increased expression of DIF-2 regardless of whether the
patients were PR3-ANCA or MPO-ANCA. The high
ANCA titer group had a 6.8 4.2-fold increase in DIF-2
versus healthy donors, P  0.05, while the low ANCA
titer group of ANCA patients had a 4.8 3.5 increase in
DIF-2. The level of serum creatinine of ANCA patients
across a range of 0.7 mg/dL to 10.7 mg/dL did not corre-
late with DIF-2 expression (data not shown).
Expression of DIF-2 protein
DIF-2 protein levels were analyzed and compared to
healthy individuals. The data indicate that protein levels
directly correlate with the mRNA levels described above.
In vitro treatment of leukocytes from healthy volunteers
with ANCA IgG resulted in increased DIF-2 protein,
compared to normal IgG treatment (Fig. 4A). Moreover,
the ANCA patient with severe disease (A; Fig. 4B,
lane 1) had a higher level of DIF-2 than those with
mild or moderate disease (Fig. 4B, lanes 2-5). DIF-2 was
below detectable levels with remission (R) of disease,
similar to healthy volunteers.
DISCUSSION
Our study provides a novel approach to study the mo-
lecular events involved in ANCA disease. Using micro-
array chip technology and quantitative, RT  PCR, we
identified genes whose expression is sensitive to ANCA
IgG and ANCA F(ab)2 regulation. The point of interest
relevant to the present discussion lies not so much in
the genes identified, but in the implication that F(ab)2
engaged the signaling components that activate tran-
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scription. In fact, while intact ANCA molecules are more
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Table 3. In vitro analysis of superoxide generation measured by SOD-inhibitable reduction of ferricytochrome C
Normal IgG PR3-ANCA IgG MPO-ANCA IgG Normal F(ab)2 PR3-ANCA F(ab)2 MPO-ANCA F(ab)2
Untreated fMLP (N  4) (N  6) (N  6) (N  4) (N  3) (N  4)
0.730.49 5.071.02 1.200.68 3.601.62 2.401.05 0.630.46 1.660.82 1.490.94
(P  0.0001) (P  0.001) (P  0.01) (P  0.001)
Values are the mean of superoxide level expressed as nmol/L O
2 /106 leukocytes/45 minutes from 6 independent experiments. In each experiment, primed leukocytes
were treated with indicated numbers of ANCA- or normal-IgG or F(ab)2 for 45 minutes. P value was specific ANCA group vs. matched normal IgG or F(ab)2 group.
in vitro and leukocytes from patients with ANCA disease
express increased levels of DIF-2, compared to patients
with SLE or IgA nephropathy. Our current study shows
that leukocyte transcription of DIF-2 increases in ANCA
patients and that the higher levels are associated with
renal disease activity. To our knowledge, these results
are the first to demonstrate that changes in leukocyte
gene expression can reflect disease activity involving kid-
ney tissue.
Why is DIF-2 increased in ANCA patients? Very little
is known about the protein’s function, but it appears to
be associated with proliferation induced by epidermal
growth factor and hepatocyte growth factor in some cell
types [20]. We know that transcription of DIF-2 is regu-
lated by the tumor suppressor p53 and by nuclear
factor-B (NF-B), implying that it is likely to be in-
volved in apoptosis and/or stress responses [21]. The
induction of this gene has been demonstrated in response
to irradiation in breast cancer cells. In human monocytes
it appears to be involved in differentiation into macro-
phages and it is expressed in circulating lymphocytes
[10]. Other agents that induce DIF-2 include 12-O-tetra-
decanoylphorbol-13-acetate, Fas, TNF-, [9], 1,25-Dihy-
droxyvitamin D3 [22], lipopolysaccharide, phorbol-12-
myristate-13-acetate, and ceramide [10].
How is signaling induced by binding of F(ab)2? This
question is yet to be worked out; however, we speculate
that the F(ab)2 serves as a tethering molecule. Clustering
or aggregation of ANCA-antigens could potentate sig-
naling, particularly if the antigens are binding other pro-
teins on the cell surface, such as Mac-1 (CD11b/CD18),Fig. 2. In vitro analysis of ANCA stimulated effects. (A) The variability
a 2 integrin involved in neutrophil signaling [23]. Manyin individual IgG and F(ab)2 preparations to stimulate superoxide
(O
2 ) release by SOD-inhibitable reduction of ferricytochrome C. Each receptor systems require clustering for transmembrane
symbol represents the average value from six separate experiments with
signaling. Other reports of ANCA signaling indicate that6 different leukocyte donors. (B) The variability in individual IgG and
F(ab)2 preparations to induce an increase in DIF-2 mRNA levels. the entire ANCA-IgG molecule can stimulate the pro-
Symbols are: () Normal 1, MPO-ANCA 1, PR3-ANCA 1; () Normal tein kinase C pathway [24]. Moreover, ANCA-induced
2, MPO-ANCA 2, PR3-ANCA 3; () Normal 3, MPO-ANCA 3, PR3-
signaling can synergize with arachidonic acid (AA) path-ANCA 3; () Normal 4, MPO-ANCA 4, PR3-ANCA 4; () MPO-
ANCA 5, PR3-ANCA 5; () MPO-ANCA 6, PR3-ANCA 6. Each ways [25] and with TNF- signaling pathways [15, 26].
symbol represents the average value from eight experiments with eight With what we understand to date, the most likely sce-
individual donors. All experiments were performed in duplicate.
nario is that ANCA integrate signals from both ANCA
F(ab)2-and ANCA Fc-mediated pathways. These signals
are probably not mutually exclusive and the complexityproficient than their corresponding F(ab)2 fragments in
of the outputs can result in a variety of neutrophil andthe activation of neutrophil activation, the F(ab)2 frag-
monocyte functions. However, depending on the contentments appear to be equal to or more proficient in induc-
and concentrations of other factors in the microenviron-ing changes in gene expression. We are very intrigued
by the finding that both leukocytes treated with ANCA ment, signaling through F(ab)2-antigen engagement could
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Fig. 3. Analysis of DIF-2 (A and D), COX-2 (B) and IL-8 (C ) expression in leukocytes from healthy volunteers (normal), from patients with
active ANCA disease (ANCA-A), from patients with ANCA disease but in remission (ANCA-R), and from patients with SLE or IgA nephropathy.
Overall ANOVA on ranked values was used to compare patient groups: DIF-2 (A and D, P  0.05), COX-2 (B, P  0.05) and IL-8 (C, P 
0.05); *P  0.05 for specific patient groups versus normal group. The bold line represents the median value.
override simultaneous activation of FcRIIa or vice part, in ANCA effects. Availability of surface antigen
on circulating neutrophils and monocytes make theseversa. A major function of signaling networks is to place
a value on a signal such that it is either dissipated or cells the logical candidates for these interactions and
certainly these cells could have an impact on diseaseconverted into further biochemical events. Conse-
quently, in the hierarchical framework of signaling net- development. Albeit our analyses were performed on
total leukocytes to circumvent cellular changes inducedworks, the strongest signal prevails ([27] and references
therein). For example, simultaneous activation of Ras by cell isolation procedures, we cannot make the distinc-
tion of whether these effects are specifically due to alter-and Rho signaling is required for optimal activation of
the IL-2 gene response to various stimuli, while a stimu- ations in gene expression by antibodies interacting with
neutrophils, as opposed to mononuclear cells, for exam-lus that selectively activate Ras or Rho signaling gives
rise to a different transcriptional response, underscoring ple. Also, we cannot rule out that these cells might have
secondary effects on lymphocytes or other cells.the importance of the transcriptional machinery in the
integration of signal inputs. There are reports showing a correlation between
higher concentrations of surface PR3 and developmentAnti-neutrophil cytoplasmic autoantibodies F(ab)2
effects on leukocytes appear to contribute to ANCA- of disease. These findings raise a crucial question of
whether patients who express high levels of PR3/MPOspecific pathological effects. Thus, the implication is that
antigen-antibody interactions are involved, at least in on the surface of neutrophils and monocytes are at risk
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Table 4. Characteristics of ANCA patients
ANCA titer Gene expression
Antigen Disease Serum creatinine
Patient specificities PR3-ANCA MPO-ANCA activity mg/dL DIF-2 COX-2 IL-8
1 008RN011 PR3-ANCA 12.0 4.0 remission 3.2 — 0.75 3.46
2a 009RN012 PR3-ANCA 74.0 3.2 active 0.8 10.49 13.07 24.96
2b 009RN013 PR3-ANCA 51.7 4.0 active 0.7 3.75 2.18 2.01
3a 015RN020 MPO-ANCA 2.9 17.3 active 1.9 9.05 2.43 1.66
3b 015RN022 MPO-ANCA 3.4 10.4 active 1.4 2.39 2.75 4.99
4a 018RN025 PR3-ANCA 102.0 3.7 remission 2.2 4.95 1.38 2.84
4b 018RN026 PR3-ANCA 82.2 3.6 remission 2.4 1.48 1.47 3.80
5 020RN028 MPO-ANCA 5.0 25.0 active 4.1 9.41 6.89 1.21
6 043RN062 MPO-ANCA 6.4 130.0 active 10.7 6.60 1.16 0.60
7a 045RN064 MPO-ANCA 6.4 79.0 remission 1.1 2.46 6.71 12.07
7b 045RN528 MPO-ANCA 2.4 86.9 active 1.0 0.72 0.11 0.33
8a 048RN067 PR3-ANCA 35.0 5.1 active 1.2 2.23 2.34 5.21
8b 048RN186 PR3-ANCA 32.0 5.4 active 1.2 4.93 2.60 3.35
9 050RN069 MPO-ANCA 4.4 4.7 remission 2.0 11.92 20.25 23.29
10a 054RN074 PR3-ANCA 74.0 5.0 active 2.2 2.81 7.13 17.38
10b 054RN228 PR3-ANCA 51.4 3.2 remission 2.4 2.15 2.35 5.62
11a 056RN076 MPO-ANCA 13.2 70.5 active — 14.75 22.03 31.93
11b 056RN257 MPO-ANCA 4.3 40.5 active 1.7 10.96 4.38 1.92
12a 058RN078 PR3-ANCA 25.5 4.5 active 1.6 17.76 22.90 31.20
12b 058RN230 PR3-ANCA 37.1 4.9 active 2.1 14.25 6.75 2.13
12c 058RN235 PR3-ANCA — — active 1.5 6.11 1.92 2.97
13 059RN079 PR3-ANCA 36.0 4.7 remission 5.5 — — 15.26
14a 064RN084 PR3-ANCA 6.9 3.7 remission 1.2 6.34 10.27 29.74
14b 064RN346 PR3-ANCA 8.5 3.0 remission 0.9 1.38 0.60 2.39
15a 066RN086 PR3-ANCA 135.0 3.3 active 0.9 2.61 2.46 0.13
15b 066RN347 PR3-ANCA 75.7 2.9 active 0.7 6.63 2.63 0.73
16a 082RN101 PR3-ANCA 30.9 3.9 active 0.6 3.22 1.86 2.85
16b 082RN380 PR3-ANCA 19.6 4.2 remission 1.0 2.52 3.29 2.95
17 096RN120 PR3-ANCA 14.0 3.0 active 6.1 5.15 6.55 17.30
18 130RN194 MPO-ANCA — — active 1.3 5.43 14.64 23.07
19 136RN206 MPO-ANCA 3.4 72.3 active 2.6 5.09 2.63 2.35
20a 137RN212 PR3-ANCA 70.6 4.5 active 3.4 9.62 3.42 0.44
20b 137RN225 PR3-ANCA 13.5 3.5 active 2.7 4.53 5.46 1.47
21 138RN213 PR3-ANCA 123.0 3.5 active 4.0 4.54 5.66 12.19
22 140RN227 MPO-ANCA 2.3 5.4 remission 1.2 2.17 3.94 4.90
23 141RN229 PR3-ANCA 85.2 4.2 active 0.7 2.32 2.31 2.92
24 142RN231 MPO-ANCA 2.3 18.5 active 4.5 1.95 0.95 4.09
25 153RN254 MPO-ANCA 3.8 20.5 active 2.4 7.90 1.23 4.52
26a 154RN258 PR3-ANCA 61.6 2.8 active 1.7 2.19 2.52 5.33
26b 154RN529 PR3-ANCA 13.9 3.1 active 2.3 7.99 3.22 1.33
27a 145RN239 MPO-ANCA 2.4 40.5 active 0.9 6.41 3.52 0.83
27b 145RN244 MPO-ANCA 2.2 28.9 active 0.8 2.51 1.31 2.03
28 158RN285 PR3-ANCA 43.6 8.4 active 0.7 3.86 2.38 4.11
29 162RN300 PR3-ANCA 167.0 2.9 active 0.9 4.36 2.46 3.17
30 168RN321 MPO-ANCA 3.4 100.3 active 9.0 4.87 2.51 4.91
31 227RN433 PR3-ANCA 104.8 3.4 active 9.2 10.37 6.19 1.50
32a 230RN438 MPO-ANCA 12.3 102.4 active 1.2 9.44 16.95 0.82
32b 230RN439 MPO-ANCA 4.7 58.0 active 1.0 3.56 1.08 1.03
32c 230RN552 MPO-ANCA 3.5 34.6 active 1.2 9.32 0.96 0.81
33 246RN474 MPO-ANCA 2.6 11.0 remission 0.9 2.61 1.75 7.32
34 247RN475 PR3-ANCA 47.0 2.9 active 1.1 3.68 2.12 2.06
for development of ANCA-mediated disease. Alterna- Our data and those of others do not support an exclusive
role of the Fc receptor engagement in ANCA-inducedtively, the presence of ANCA in the circulation may
prime the neutrophils prematurely, thus causing PR3 effects [15, 29]. However, it has been demonstrated by
other groups that ANCA Fc activation of FcRIIa is theor MPO plasma membrane expression and enhancing
ANCA-binding. A recent report has introduced the con- primary mechanism of activation [30, 31]. The domi-
nating IgG subclass distribution of PR3-ANCA has beencept that subsets of neutrophils express PR3 molecules
on their surface and that the proportion of neutrophils shown to be IgG1, with a small subset of IgG4 [32, 33].
The IgG3 subclass for MPO-ANCA was totally lackingpresenting PR3 is genetically controlled and highly stable
[28]. Indeed, the authors found that the phenotype of in the group of patients tested by Mellbye, Mollnes and
Steen [33], similar to published work by Locke, Leakerincreased PR3 surface expression was significantly in-
creased in patients with ANCA-associated vasculitis. and Cambridge showing that MPO-ANCA in sera from
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levels than patients with the highly active disease. Close
inspection of the data indicated that patients categorized
as ANCA also had higher levels of IL-8, although not
statistically significant. A larger sample size in the ANCA
group would be needed to make accurate comparisons.
Intuitively, one would expect IL-8 to be highest during
the peak of disease activity. How do we explain what
appears to be a functional disparity? Biologically IL-8
appears to have two functions, first to induce neutrophil
migration along a gradient of factor toward a specific
site of secretion, and second to play a role in angiogenesis
(references in [40]). We speculate that patients approach-
ing remission or in remission may be undergoing a tissue
recovery process, of which angiogenesis may be involved.
Clearly, the mechanisms utilized by IL-8 to distinguish
one effect from the other needs to be resolved. One
possibility is that function is determined by receptor
binding, as there are at least two classes of receptors
that bind IL-8 [41]. Another possibility is that an increase
Fig. 4. DIF-2 protein levels. (A) In vitro exposure of cells to ANCA- in biological analogs of IL-8 may compete for receptors
or normal-IgG: lane 1,TNF--primed control; lane 2, normal IgG (N1); and would influence the effects of IL-8 [42]. For example,lane 3, MPO-ANCA IgG(P1); lane 4, MPO-ANCA (P3); lane 5, PR3-
ANCA IgG(C1). (B) Analysis of leukocytes from ANCA patients at Gro-beta, an analog of IL-8, was increased by ANCA
different stages of disease: lanes 1, severe disease activity (A); lane in the microarray in vitro activation studies (Table 2).
2, moderate disease activity (A); lanes 3-5, mild disease activity (A);
Gro-beta could compete for receptors, thus swaying thelane 6, remission (R); lanes 7-9, healthy volunteers (N). Proteinase
3 (PR3) Western blots are given as a reference for protein loading binding and activity of IL-8.
comparisons. Exploration of the mechanisms of ANCA-induced
pathogenicity has resulted in reports that seemingly con-
flict. A number of technical obstacles inherent in the use
of human neutrophils and monocytes explain part of thepatients with active vasculitis was primarily of the IgG4
confusion. One complexity of studying ANCA-inducedsubclass [34]. Although one report has indicated that
effects is the variability of leukocyte responses from do-there is an increase in IgG3 subclass during active disease
nor-to-donor, and the variability of leukocyte responses[35]. The receptor that is mainly involved in the neutro-
within any one individual due to the day-to-day varia-phil activation process, FcRIIa, has particular affinity
tions. Moreover, the ANCA-IgG molecules may vary infor the IgG3 subclass [36]. It exists in the population as
their potency due to differences in epitope specificity,polymorphic variants and neutrophils homozygous for
affinity and other factors. At present it is reasonable tothe FcRIIa-H131 allotype and bind more efficiently
presume that both parts of the immunoglobulin moleculeto IgG3. This finding spurred the question of whether
effectively signal leukocyte activation. In vivo, the inten-individuals who are homozygous for FcRIIa-H131 are
sity and regulation of these signals may provide somemore susceptible to developing ANCA-associated sys-
explanation for the spectrum of disease severity. How-temic vasculitis and nephritis due to differential IgG
ever, the full spectrum of biologic diversity is certainlybinding and activation. However, no skewing of the
caused by a number of factors including differences inFcRIIa-H131 allotype was found among patients irre-
antigen expression, host leukocyte activation, the typespective of ANCA specificity, and no association was
and amount of circulating chemokines and cytokines,found between the FcRIIa allotype and nephritis [37, 38].
the state of the endothelium, and the nature of T and BThe conclusions of these investigators were that circulat-
cell interactions.ing MPO-ANCA do not significantly bind FcRIIa, and
FcRIIa-independent mechanisms should be explored. Reprint requests to Jia Jin Yang, M.D., Division of Nephrology,
Department of Medicine, The University of North Carolina, CB# 7155,The implication would be that FcRIIa-ANCA interac-
306 MacNider Bldg., Chapel Hill, North Carolina, 27599-7155, USA.tions are not solely responsible for ANCA-induced neutro- E-mail: jjyang@med.unc.edu
phil effects and that ANCA have an effect on neutrophils
and monocytes that is different from other immunoglob- REFERENCES
ulin molecules [4, 39].
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